Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the in vivo drug interaction between firmonertinib and paxlovid

Due to the potential occurrence of drug interactions, the combined application of firmonertinib and paxlovid carries a relatively high risk. Nevertheless, as of now, there has been no comprehensive research on the interaction between firmonertinib and paxlovid. Our aim was to establish and validate...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Peng-Fei Tang, Su-Su Bao, Wei-Fei Xie, Zhong-Xiang Xiao, Xue-Meng Wu, Hong-Lei Ge
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2025-05-01
Seri Bilgileri:	Frontiers in Pharmacology
Konular:	firmonertinib drug interactions UHPLC-MS/MS pharmacokinetics paxlovid
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1570206/full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!